Tocilizumab biosimilar - BioGen/Bio-Thera Solutions
Alternative Names: BAT-1806; BIIB-800; Shireli; Tocilizumab-bavi; TOFIDENCE; TOFIDENCETMLatest Information Update: 13 Jul 2026
At a glance
- Originator Bio-Thera Solutions
- Developer Bio-Thera Solutions; Biogen; Organon
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cytokine release syndrome; Giant cell arteritis; Juvenile rheumatoid arthritis; Rheumatoid arthritis
- Registered COVID 2019 infections
Most Recent Events
- 10 Jun 2026 Registered for COVID-2019 infections (In children, In adolescents, In adults) in USA (IV, Injection)
- 10 Jun 2026 Registered for Cytokine release syndrome (In children, In infants, In adults) in USA (IV, Injection)
- 22 Aug 2025 Bio-Thera Solutions and STADA Arzneimittel AG agreed to extend their biosimilars alliance to include Tocilizumab, for the treatment of inflammatory conditions, in the European Union, the UK, Switzerland, and selected other countries